We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.24%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.94B
AUM Growth
-$224M
Cap. Flow
-$1.92B
Cap. Flow %
-24.14%
Top 10 Hldgs %
74.98%
Holding
115
New
11
Increased
21
Reduced
12
Closed
7
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TBRA
101
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
-44,444
Closed -$2.72M
ITMN
102
DELISTED
INTERMUNE INC
ITMN
-4,722,869
Closed -$209M
QCOR
103
DELISTED
QUESTCOR PHARMA INC
QCOR
-500,000
Closed -$46.2M

Similar funds

Baker Bros. Advisors's Q3 2014 Portfolio in Review

As of Q3 2014, Baker Bros. Advisors held 115 positions worth $7.94B, down 2.7% from $8.16B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Baker Bros. Advisors withdrew a net $1.92B in Q3 2014, closing 7 positions and reducing 12 holdings. Its most notable exit was INTERMUNE INC, an estimated $209M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 40% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $18.2M.

  • Baker Bros. Advisors's largest Q3 2014 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 201,856 shares worth $18.2M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q3 2014, an estimated $30.4M increase.
  • Baker Bros. Advisors's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $18.1M.
  • Baker Bros. Advisors fully exited INTERMUNE INC in Q3 2014, selling an estimated $209M.
  • Baker Bros. Advisors's ten largest holdings make up 75% of its $7.94B portfolio in Q3 2014.
  • Baker Bros. Advisors opened 11 new positions and closed 7 in Q3 2014.
  • Baker Bros. Advisors's portfolio value fell 2.7% quarter-over-quarter to $7.94B.

Based on Baker Bros. Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.